Epizyme (EPZM) PT Lowered to $12 at Cowen, Following Earnings

Cowen analyst Joseph Thome lowered the price target on Epizyme (NASDAQ: EPZM) to $12.00 (from $14.00) while maintaining a Outperform rating.

Analyst comments: "Q3 Tazverik revenues came in below consensus; however, a focus on expanding Tazverik's reach via changes in commercial strategy and clinical and geographical expansion could improve the outlook in the long-term. Advancement in Tazverik combination basket studies for heme and solid tumors and the Ph. I for EZM0414 is a key area of focus over the coming months."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• TD Cowen Reiterates Buy Rating on Tesla (TSLA), well-positioned to scale in US AV market